Genome-wide mrna and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3105-3114

  Gmeiner, William H ^a   Reinhold, William C ^b   Pommier, Yves ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; GLYCOSYLTRANSFERASE; IRINOTECAN; MESSENGER RNA; MICRORNA; NSC 616348; NSC 697912; NUCLEOSIDE DIPHOSPHATASE; TOPOTECAN; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE;

ANXA6 GENE; APPBP2 GENE; ARTICLE; CLTC GENE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG STRUCTURE; ENDOCYTOSIS; GENE; HUMAN; HUMAN CELL; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; RNA ANALYSIS; SNF8 GENE;

CAMPTOTHECIN; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOCYTOSIS; FLOXURIDINE; FLUORODEOXYURIDYLATE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MICRORNAS; NATIONAL CANCER INSTITUTE (U.S.); NUCLEOSIDES; RNA, MESSENGER; TOPOISOMERASE I INHIBITORS; TOPOTECAN; UNITED STATES;

EID: 78650448417     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0674     Document Type: Article

References (39)

1. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35.
2. Weinstein JN, Pommier Y. Connecting genes, drugs and diseases. Nat Biotechnol 2006;24:1365-6.
3. Bonnefoi H, Underhill C, Iggo R, Cameron D. Predictive signatures for chemotherapy sensitivity in breast cancer: Are they ready for use in the clinic? Eur J Cancer 2009;45:1733-43.
4. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of a mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
5. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24: 236-44. (Pubitemid 30132190)
6. Liu H, D'Andrade P, Fulmer-Smentek S, et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 2010;9:1080-91.
7. Holbeck SL, Collins JM, Doroshow JH. Analysis of food and drug administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 2010;9:1451-60.
8. Zaharevitz DW, Holbeck SL, Bowerman C, Svetlik PA. COMPARE: A web accessible tool for investigating mechanisms of cell growth inhibition. J Mol Graph Pad 2002;20:297-303.
9. Liao Z-Y, Sordet O, Zhang H-L, et al. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase IDNA complexes. Cancer Res 2005;65:4844-51.
10. Boyd M, Paull K. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91-109.
11. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66.
12. Shankavaram UT, Reinhold WC, Nishizuka S, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: An integromic microarray study. Mol Cancer Ther 2007;6:820-32.
13. Reinhold WC, Mergny JL, Liu H, et al. Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res 2010;70:2191-203.
14. Liu H, D'Andrade P, Fulmer-Smentek S, et al. mRNA and microRNA expression profiles integrated with drug sensitivities of the NCI-60 human cancer cell lines. Mol Cancer Ther 2010; 9:1080-91.
15. Wu Z, Irizarry RA. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol 2005;12:882-93.
16. Irizarry RA, Bolstad BM, Collin F, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
17. Bijnsdorp IV, Comijn EM, Padron JM, Gmeiner WH, Peters GJ. Mechanisms of action of FdUMP[10]: Metabolite activation and thymidylate synthase inhibition. Oncol Rep 2007;18:287-91.
18. Henne WM, Boucrot E, Meinecke M, et al. FCHo proteins are nucleators of clathrin-mediated endocytosis. Science 2010;328: 1281-4.
19. Im YJ, Hurley JH. Integrated structural model and membrane targeting mechanism of the human ESCRT-II complex. Dev Cell 2008;14:902-13.
20. Grewal T, Enrich C. Annexins - Modulators of EGF receptor signaling and trafficking. Cell Signal 2009;21:847-58.
21. Hirasawa A, Saito-Ohara F, Inoue J, et al. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003;9:1995-2004.
22. Gmeiner WH. Genetic determinants for activated fluoropyrimidine chemotherapy. Drug Dev Res 2006;67:119-29.
23. Gmeiner WH. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 2005;12:191-202.
24. Gmeiner WH, Trump E, Wei C. Enhanced DNA-directed effects of FdUMP[10] compared to 5-FU. Nucl Nuct Nucl Acids 2004;23:401-10.
25. Kim S, Park D-H, Kim TH, Hwang M, Shim J. Functional analysis of pyrimidine biosynthesis enzymes using the anticancer drug 5-fluorouracil in Caenorhabditis elegans. FEBS J 2009;276:4715-26.
26. Pritchard DM, Watson AJM, Potte CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation. Proc Natl Acad Sci U S A 1997;94:1795-9.
27. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007;43:1011-6.
28. Desvignes T, Pontarotti P, Fauvel C, Bobe J. Nme protein family evolutionary history, a vertebrate perspective. BMC Evol Biol 2009;9:256-81.
29. Steeg PS. Tumor metastasis:mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
30. Condac E, Silasi-Mansat R, Kosanke S, et al. Polycystic disease caused by deficiency in xylosyltransferase 2, an initiating enzyme of glycosaminoglycan biosynthesis. Proc Natl Acad Sci U S A 2007;104:9416-21.
31. Love DC, Krause MW, Hanover JA. O-GlcNac cycling: Emerging roles in development and epigenetics. Semin Cell Dev Biol 2010; (in press).
32. Pfister TD, Reinhold WC, Agama K, et al. Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther 2009;8:1878-84.
33. Goldwasser F, Bae IS, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995; 55:2116-21.
34. Nieves-Neira W, Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the eight human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationship with topoisomerase I, protein kinase C, bcl-2 and caspase pathways. Int J Cancer 1999;82:396-404.
35. Pommier Y. DNA topoisomerase I inhibitors: Chemistry, biology, and interfacial inhibition. Chem Rev 2009;109:2894-902.
36. Wang Y, Lee ATC, Ma JZI, et al. Profiling mircoRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-22-specific target. J Biol Chem 2008;283:13205-15.
37. Mishra PJ, Song B, Mishra PJ, et al. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One 2009;4:e8445.
38. Temmink OH, de Bruin M, Laan AC, et al. The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells. Int J Biochem Cell Biol 2006;38:1759-65.
39. Brody JR, Hucl T, Costantino CL, et al. Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. Cancer Res 2009;69:984-91.